Immix Biopharma Investor Presentation Deck
NXC-201 - First CAR-T in AL Amyloidosis, a $6 billion market by 2025
Johnson & Johnson
DARZALEX
(daratumumab)
22%
in a sus fue
00 mm 400 mg/20 m
55%
Investigator's
Choice
NM
response rates in relapsed/refractory AL Amyloidosis
NXC-201
I Best Hematologic
Response and
I Cardiac Response
NM
AstraZeneca
CAELUM
BIOSCIENCES
CAEL-101
100%
Hematologic Overall Response Rate
prothena
Birtamimab
-
39%
NXC-201
35%
I 61%
Median Reduction from baseline NT-proBNP
●
●●●
IMMIX
S BIOPHARMA
NXC-201 Only CAR-T in AL
Amyloidosis
NXC-201 100% Overall
Response Rate in
relapsed/refractory AL
amyloidosis (median 6 lines of
therapy prior to NXC-201 - all
including Darzalex)
Cardiac Response exceeds
purpose-designed CAEL-101 and
Birtamimab for relapsed/
refractory patients
Zero Neurotoxicity of any grade
in AL Amyloidosis
Birtamimab Source: Gertz MA et al. J Clin Oncol. 2016;. CAEL-101 source: Edwards CV, et al. Blood. 2021 Darzalex source: Theodorakakou, et al, 2022-Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy - Blood (2022) 140 (Supplement 1): 4275-4276 https://doi.org/10.1182/blood-2022-165403, Point-of-care CART
manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11. Assayag, M, et al. Stepensky. Point-of-care CART manufacture and
delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting. 2023 Apr 23-26. Asherie N. et al, Oral Presentation. ASGCT, 2023.The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in
2025, according to Grand View Research. Lebel E, et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting, 2023. Differences exist between trial designs and subject characteristics, and caution
should be exercised when comparing data across studies.. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.
13View entire presentation